Lbm415

PDF inhibitor

Community

Phase I

will be in the hospital and in the market. However, such compounds clearly demonstrate that almost all pharmaceutical companies, the big ones as well the smaller, more biotech-like ones, are still willing and able to bring novel derivatives into development if they fulfill a medical need, especially with respect to overcoming resistance traits of clinical importance. In fact, at least some such novel compounds, even though derived from existing classes, deserve to be described as novel classes, as they have overcome several important and previously class-inherent disadvantages. Nevertheless, despite this (still insufficient) progress, it is generally noted with some disappointment that the large investment put into modern target- and genomic-based discoveries has apparently failed to deliver the urgently needed novel antibiotics. This leads us to the next question: What direction will the future search for novel antibiotics take?

0 0

Post a comment